- Coronavirus disease (COVID-19)
- Health Canada Toolkit: COVID-19 and substance use
- NEW – CRISM National Rapid Guidance Documents
Supporting people who use substances in shelter settings during the COVID-19 pandemic
- Telemedicine support for addiction services
- Supporting people who use substances in acute care settings during the COVID-19 pandemic
- Medications and other clinical approaches to support physical distancing for people who use substances during the COVID-19 pandemic
- Harm Reduction Resource Hub
- BCCSU Resources
Modeled partly after the Clinical Trial Network of the National Institute on Drug Abuse (NIDA), the CRISM provides a functional Canada-wide interventional research network in the field of substance misuse, where members work together to generate the knowledge base necessary to improve current addiction treatment paradigms.
CRISM was designed to facilitate communication and collaboration among addiction service providers, researchers, and policy-makers. In September 2015, four regional CRISM Nodes, one each located in British Columbia, the Prairies (Alberta, Manitoba, Saskatchewan), Ontario, and the Quebec-Atlantic region (Nova-Scotia, Newfoundland and Labrador, New Brunswick and Prince-Edward-Island), began operations.
The Quebec-Atlantic Node plans to contribute to the CRISM consortium with projects that accelerate the transfer of scientific knowledge towards the development of new treatments, including pharmaceutical approaches and psychological interventions for drug users.
The Node’s researchers and collaborators have developed different areas of expertise that will inform multi-site observational studies and randomized controlled clinical trials (RCT) on the various care options for people with a substance misuse problem, as well as on the development and evaluation of new evidenced-based preventive methods, through grants funded by CIHR and other provincial and international financing bodies.